Antigen | Parameters of immunogenicity | Group 1 (N = 151) | Group 3 (N = 148) | p-value |
---|---|---|---|---|
Tetanus | GMT fold increase (95% CI) | 8.6 (6.6–11.2) | 8.5 (6.5–11.2) | 0.47 |
GMT (95% CI) | ||||
Pre-vaccination | 0.05 (0.04–0.06) | 0.07 (0.06–0.08) | 0.01 | |
1 month post-vaccination | 0.43 (0.34–0.54) | 0.59 (0.46–0.75) | 0.06 | |
Pre-vaccination antibody titer | ||||
≥ 0.1 U/mL, No. (%) | 28 (18.5) | 31 (20.9) | 0.66 | |
Post-vaccination antibody titer | ||||
≥ 0.1 U/mL, No. (%) | 128 (84.8) | 130 (87.8) | 0.50 | |
≥ 0.5 U/mL, No. (%) | 40 (26.5) | 75 (50.7) | < 0.01 | |
Diphtheria | GMT fold increase (95% CI) | 13.0 (9.1–18.5) | 7.9 (5.4–11.7) | 0.14 |
GMT (95% CI) | ||||
Pre-vaccination | 0.07 (0.07–0.08) | 0.08 (0.07–0.10) | 0.36 | |
1 month post-vaccination | 0.96 (0.70–1.34) | 0.67 (0.50–0.90) | 0.10 | |
Pre-vaccination antibody titer | ||||
≥ 0.1 U/mL, No. (%) | 54 (35.8) | 48 (32.4) | 0.71 | |
Post-vaccination antibody titer | ||||
≥ 0.1 U/mL, No. (%) | 120 (79.5) | 120 (81.1) | 0.77 | |
≥ 0.5 U/mL, No. (%) | 96 (63.6) | 91 (61.5) | 0.72 |